USPTO serial 79085755
Serial No. 79085755
Reviewed by CopyMark Law Group
Reg. 3972716Status 709
- Filing date
- Status date
- Registration date
- Jun 7, 2011
- Examiner
- ROACH, APRIL K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 79085755?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Norman H. Zivin
Norman H. Zivin COOPER & DUNHAM LLP30 Rockefeller Plaza20th FloorNew York, NY 10112Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the treatment, cure, mitigation or prevention of gingivitis, halitosis, stomatitis, periodontitis, inflammation of the oral cavity and pharyngeal cavity, hypersensitivity of teeth, angina, atherosclerosis, bronchial asthma, circulatory disorders, constipation, diarrhea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting, allergy, gynecological disorders affecting menstruation, sterility, menstrual syndromes, dysmenorrhoea, infertility, genital tract infections, pelvic inflammatory diseases, vaginal discomfort due to menopausal atrophic changes, anatomical abnormalities of the head, the extremities, chest, abdomen and organs, neoplasia, breast neoplasm, breast cancer, mastopathy, mastodynia, premenstrual syndrome, climacteric complaints, breast pain, blood conditions and disorders, blood circulation disorders, high blood pressure, hypertension, pulmonary diseases, heart rhythm disorders, heart failure, urological diseases, sexually transmitted diseases and inflammatory pelvic diseases, menopausal complaints due to therapeutically induced menopause, tamoxifen induced hot flashes of breast cancer survivors, climactic sleep disturbances, depressive moods, protection of the skeletal system, osteoporosis, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, spinal cord diseases, psycho vegetative disorders, depressive syndrome, anxiety, nervous unrest, peripheral nervous system infections, peripheral nervous system movement disorders, nerve compression syndromes, neuritis, neuralgia and regional pain syndromes, diseases and disorders of the kidney, urological disorders, chronic infections of the bladder, cystitis, pyelonephritis, glomerulonephritis, interstitial nephritis, nephrolithiasis, cancer, urolith prophylaxis, dizziness, migraine, depression, inflammations of the upper and lower respiratory organs, sinuses, bronchitis, tonsillitis, arthritis, osteoarthritis, fever, cough, cold, Alzheimer's disease, infection of respiratory tract, infection of urinary tract, urinary obstruction, chronic venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, musculoskeletal disease, liver disease, hepatitis, cirrhosis of liver, periodontal diseases and dental caries; pharmaceutical preparations for use as an antidepressant, diuretic, hypnotic, sedative, analeptic, and tranquilizer; haemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparations, non-narcotic analgesics, throat lozenges; medicinal preparations in tablet form, namely, menstruation circulation regulating tablets; pharmaceutical preparations, namely, for hormone regulation and hormone replacement; pharmaceutical preparations for sensory organs, namely, for use in ophthalmology, otolaryngology and dermatology; pharmaceutical preparations for regulation and strengthening of the immune system, pharmaceutical preparations for treating of and providing temporary relief for occasional minor irritation, pain, sore mouth, sore gums, sore throat, pain associated with canker sores, pain due to minor irritation or injury of the mouth and gums, pain due to minor dental procedures, pain due to minor irritations caused by dentures or orthodontic appliances, sore gums due to teething in infants and children four months of age and older; pharmaceutical products, namely, medicated dental, gum and mouth washes, medicated dental, gum and mouth rinse, medicated toothpastes, medicated oral-care gels, medicated dental gels, medicated lozenges, cough lozenges, medicated chewing gum, medicated gels and fluids in the nature of medicated balms, medicated dental tapes, medicated dental ribbons, medicated dental polish; pharmaceutical preparations for dental purposes, namely, plaque disclosing reagents, periodontal diagnostic reagents for medical purposes for detecting derivatives from periodontal bacteria and caries, diagnostic reagents for detecting derivatives from caries-causing bacteria and medicines for the prevention and treatment of periodontal diseases, dental caries, canker sores, cold sores, mucositis and oral and tongue cancers; sanitary preparations for medical use; sanitary preparations for hygiene, namely, antiseptics, oral antiseptics, disinfectants for health purposes; medicated sanitary preparations for the treatment, cleaning and protection of the skin; dietary supplements in the form of tablets, drops, capsules, extract preparations, balms or in liquid form, containing plant extracts; dietetic substances adapted for medical use, namely, dietetic foods, dietetic beverages, dietetic sugar, dietetic food supplements; medical and surgical plasters; plant extracts for pharmaceutical purposes and plant extracts used as dietetic substances adapted for medical use; nutritional additives for medical purposes, namely, dietary and nutritional supplements for human consumption; medicinal oils; vitamin and mineral supplements; food and food supplements, namely, herbal teas for medicinal purposes and medicinal teas; medicinal herbs; materials for dressings, namely, gauze and bandages; all purpose disinfectants | SECTION 71 - CANCELLED | — |
| 041 | Educational services, namely, providing classes and workshops in the field of health, health consciousness and health queries to medical practitioners, health specialists and/or patients, providing of training in particular providing information about education in the field of health, health consciousness and health queries for medical practitioners, health specialists and patients, also via the Internet | SECTION 71 - CANCELLED | — |
| 044 | Medical services; hygienic and beauty care for human beings; medical consultancy, consultancy in the fields of pharmaceutical advice and health, also via the Internet | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 2, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 8, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 11, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 22, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 22, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 17, 2020 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Dec 6, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 4, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 19, 2018 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 28, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 17, 2018 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Sep 17, 2018 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Sep 12, 2018 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 12, 2018 | C71T | CANCELLED SECTION 71 | — |
| Jun 12, 2014 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 26, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 6, 2012 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 22, 2012 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 1, 2011 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 1, 2011 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 7, 2011 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 7, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 22, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 22, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 3, 2011 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 3, 2011 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 17, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 11, 2011 | ALIE | ASSIGNED TO LIE | — |
| Jan 18, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 18, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 18, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 18, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 18, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 11, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 11, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 11, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2010 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 1, 2010 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 5, 2010 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 5, 2010 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 5, 2010 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 4, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 4, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 7, 2010 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 3, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 2, 2010 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |